Breast cancer (BC) is a heterogeneous disease which many studies have classified in at least four molecular subtypes: Luminal A, Luminal B, HER2-Enriched, and Basal-like (including triple-negative breast cancer, TNBC). These subtypes provide information to stratify patients for better prognostic predictions and treatment selection. Individuals vary in their sensitivities to carcinogens due to differences in their DNA repair capacity (DRC) levels. Although our previous case-control study established low DRC (in terms of NER pathway) as a BC risk factor, we aim to study this effect among the molecular subtypes. Therefore, the objectives of this study include investigating whether DRC varies among molecular subtypes and testing any association...
Abstract Background Breast cancer is the most common cancer in women. 12–15% of all tumors are tripl...
Stratification of oestrogen receptor (ER) negative and triple negative breast cancers (TNBCs) is urg...
Introduction: In triple negative breast cancers (TNBC) the initial response to chemotherapy is often...
Abstract Background Previous studies have found a link between a low DNA repair capacity (DRC) level...
Background. According to the literature, BRCA1-associated breast cancer (BC) most often belongs to t...
DNA repair is a key determinant in the cellular response to therapy and tumor repair status could pl...
Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide and is the leading cause...
Abstract Triple Negative Breast Cancer (TNBC), negative for estrogen, progesterone and Her2 receptor...
BACKGROUND: Screening mammography has had a positive impact on breast cancer mortality but cannot de...
Triple negative breast cancers (TNBCs) represent about 15–20% of all breast cancer cases and are cha...
Thedevelopment of drug-biomarker combinations holds prom-ise for tailoring treatment for patients wi...
Introduction: BRCA-mutated breast cancer cells lack the DNA-repair mechanism homologous recombinatio...
Item does not contain fulltextBACKGROUND: We have previously reported an array comparative genomic h...
The BRCA1 gene product helps to maintain genomic integrity through its participation in the cellular...
Triple-negative breast cancer (TNBC) is a subtype of aggressive breast cancer and characterized by a...
Abstract Background Breast cancer is the most common cancer in women. 12–15% of all tumors are tripl...
Stratification of oestrogen receptor (ER) negative and triple negative breast cancers (TNBCs) is urg...
Introduction: In triple negative breast cancers (TNBC) the initial response to chemotherapy is often...
Abstract Background Previous studies have found a link between a low DNA repair capacity (DRC) level...
Background. According to the literature, BRCA1-associated breast cancer (BC) most often belongs to t...
DNA repair is a key determinant in the cellular response to therapy and tumor repair status could pl...
Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide and is the leading cause...
Abstract Triple Negative Breast Cancer (TNBC), negative for estrogen, progesterone and Her2 receptor...
BACKGROUND: Screening mammography has had a positive impact on breast cancer mortality but cannot de...
Triple negative breast cancers (TNBCs) represent about 15–20% of all breast cancer cases and are cha...
Thedevelopment of drug-biomarker combinations holds prom-ise for tailoring treatment for patients wi...
Introduction: BRCA-mutated breast cancer cells lack the DNA-repair mechanism homologous recombinatio...
Item does not contain fulltextBACKGROUND: We have previously reported an array comparative genomic h...
The BRCA1 gene product helps to maintain genomic integrity through its participation in the cellular...
Triple-negative breast cancer (TNBC) is a subtype of aggressive breast cancer and characterized by a...
Abstract Background Breast cancer is the most common cancer in women. 12–15% of all tumors are tripl...
Stratification of oestrogen receptor (ER) negative and triple negative breast cancers (TNBCs) is urg...
Introduction: In triple negative breast cancers (TNBC) the initial response to chemotherapy is often...